The new discoveries, the extraordinary dynamism in human stem cell (SC) research, and the great expectations of the benefi ts in clinical treatment of many diseases are on the edge of unparalleled advances in both: 1) the understanding of basic mechanisms of cell diff erentiation and development and 2) the translation from basic research to new clinical therapies. Human stem cells are obtained from diff erent sources, such as embryo, fetal, and adult tissues, in vitro induction (iPS cells) or transdiff erentiation. The evidence that these cells are pluripotent (or multipotent), meaning they have the ability to diff erentiate into all body tissues or tissues of the same lineage, raises the possibility that they could regenerate diseased or damaged tissue in diseases that until now have had no eff ective treatments. Human stem cell research and therapy raise important bioethical considerations because of the human nature of these cells and their peculiar characteristics. Here we discuss the bioethical aspects of basic human SC research and the conditions necessary for the translation of basic preclinical research into clinical use of SC.
INTRODUCTION
The production and use of human stem cells (SC), especially embryonic stem cells (ES) has attracted major scientifi c and public interest for two reasons: 1) From the scientifi c perspective, the evidence that these cells are pluripotent, meaning they have the ability to diff erentiate into all body tissues raises the possibility that they could regenerate diseased or damaged tissue in diseases that until now had no eff ective treatments (Andersson and Lendahl, 2009; Lindvall and Hyun, 2009; Riazi et al., 2009 ). This has resulted in high expectations in the media and public about treatments and eventual cures for a wide range of diseases, some of which have no eff ective treatment and mean painful situations for patients and their families, such as Alzheimer's disease, Parkinson's disease and Amyotrophic Lateral Sclerosis. Taking into consideration the rapid development of human SC research, there is a vast amount of information off ered to patients, researchers, clinicians and members of the public. This information may be in many aspects questionable and presented in the media uncritically (Peddie et al., 2009) . Sometimes scientists themselves, in interviews in the media contribute to expectations that are not consistent with the current state of SC use in human medical treatments (Choumerianou et al., 2008; Devereaux and Loring, 2010) . 2) The other aspect discussed in the scientifi c literature and media is the ethical issues involved in how SC are obtained (for example from human embryos), how they are stored and how are they used in Medicine (Gómez-Lobo, 2004; Knoepffl er, 2004) .
AIM OF THIS PAPER
We discuss the bioethical aspects involved in basic SC research and the conditions necessary for the translation of preclinical basic research to the clinical use of SC. Furthermore, we deal with the sometimes thin line between legitimate medical innovation and off ers of treatments that do not fulfi ll ethical and scientific standards but nevertheless excite anxious patients who fi nd these treatments outside of regular medicine in what has been called "SC tourism"
Defi nition and types of SC
There are several types of human SC: embryonic stem cells (ESC), adult stem cells (ASC), induced pluripotent stem cells (iPS) and reprogrammed adult diff erentiated cells obtained by transdiff erentiation.
All SC have the following characteristics: they are undiff erentiated cells, i.e. they are not specialized or specifi c like the cells of diff erent tissues; they can replicate themselves and they maintain their differentiation potential and may eventually regenerate various tissues (Álvarez et al., 2012) .
The diff erent types of SC diff er in their origin, potential to generate various tissue and adverse eff ects when used in living organisms. Until recently only two types and ways to obtain stem cells were available. However, in 2006 Yamanaka and his group produced stem cells with embryonic characteristics by reprogramming diff erentiated cells from the skin. These stem cells were called induced pluripotent (iPS) cells (Takahashi and Yamanaka, 2006) . More recently, direct transdiff erentiation was obtained between two types of fully diff erentiated adult cells, thus bypassing the pluripotential state (Vierbuchen, 2010) .
Embryonic stem cells (ESC)
In 1981, Evans and Martin successfully isolated and cultured in vitro the inner cell mass cells of mouse blastocyst. Since these cells can diff erentiate into various tissues of the body, they are called pluripotent. These in vitro cultured cells are called embryonic stem (Evans, 2011) . This was a landmark advance in the understanding of development, tissue homeostasis and progress of Regenerative Medicine. Then, in 1998 inner mass cells from a human blastocyst were successfully cultured (Conaghan J, et al. 1998) . The main feature of ESC cells is the ability to multiply indefi nitely in vitro while maintaining their pluripotent nature and the ability to be biologically manipulated to diff erentiate into diff erent cells of various tissues
Adult Stem Cells (ASC)
Adult stem cells are found in various tissues of an organism already formed and are able to form and regenerate cell lines from a particular tissue or tissues. This feature is called multipotency. ASC may be cultured in vitro but this is more diffi cult compared with multiplication of ESC (Schuijers and Clevers, 2012) . The most studied and clinically used ASC are the hematopoietic and mesenchymal cells in bone marrow. It is also possible to obtain this type of cells from the cord blood (Rao et al., 2012) and from the umbilical cord (Hayward et al., 2012) .
Fetal Stem Cells (FSC)
Pluripotent stem cells are also found in fetal tissues, called Fetal Stem Cells (Ryan et al., 2011) . FSC have also been found recently in amniotic fl uid (Antonucci et al., 2012) .
Induced pluripotent stem (iPS) cells
Being able to reprogram somatic cells to the pluripotent state through the introduction of specifi c genes was considered almost impossible. However this was experimentally done and at present is an important way to obtain pluripotent stem cells. Research in the production and use of iPS cells has followed a rapid advance (Takashi and Yamanaka, 2006; Pietronave and Prat, 2012) .
Transdiff erentiated cells
Finally, we should mention that transdiferenciation of ASCs have been achieved (Liu and Chang, 2006) and more recently direct reprogramming of somatic cells in cardiomyocytes and nerve cells has been achieved. This is called direct transdiff erentiation which bypasses the pluripotent state with the advantage of reducing the chances of producing tumors (Vierbuchen, 2010; Yang, 2011) . Nevertheless total risks of this type of cells have not yet been resolved (Pournasr et al., 2012) 
BIOETHICAL ISSUES INVOLVED IN HUMAN STEM CELL BASIC RESEARCH

Embryonic SC
The main ethical issue in obtaining human ESC is the use and destruction of human embryos. Decades of biology has shown that a new human organism begins at fertilization (Haeckel, 1912; Gilbert, 2006) . By basic conceptual logic, a human organism is a human being. This is the today focus of discussion in terms of the anthropological ethics dealing with whether the human being at this stage of development is morally relevant and has the right to the inviolability of life at this period (Valenzuela, 2007; Zarcseczny and Caulfi eld, 2009; Santos and Ventura-Juncá, 2009; Shoemaker, 2010; VenturaJuncá and Santos, 2011) . For some people, the personhood of a human embryo is reached at a later phase of development (for example at the 14th day of development), therefore the destruction of this so-called pre-embryo to obtain ESC form blastocysts (5-7th day) is morally acceptable (Wells, 1984) .
Source of human embryos to obtain ESC
Embryos regularly obtained by IVF ("surplus" embryos):
These are embryos obtained by IVF that are not used for implantation and are stored frozen at -180°C (Brett S et al., 2009) . Informed consent of the parents is required to use these embryos. Parents should understand that their embryos will be destroyed and parts will be used (inner cell mass) to obtain stem cells for research or in clinical applications. In some countries, such as the USA, a waiver of consent is permitted, thus allowing the use of embryos for research. (Editorial Science, 2006) . The production of human embryos by cloning represents a major ethical issue in that the production of cloned humans undermines human dignity by making a person into a product.
Production of new human embryos
ESC produced by "parthenogenetic embryos":
Parthenogenesis is a form of reproduction in which an unfertilized egg develops into a new individual. The fi rst pESC lines derived from human parthenotes were obtained by Revazova et al. (2007) and Revazova et al. (2008) . The main ethical question arising is whether a parthenote blastocyst is an altered human embryo or just a ball of cells without organization. This is a major anthropological question, with significant ethical consequences. The discussion continues and at the center is the question of the ontological status of parthenotes, which needs to be established before activated oocytes can be considered as an ethical source for pluripotent stem cells (Rao et al., 2008) .
Production of ESC without destroying human embryos:
The ethical objections in obtaining human ESC have encouraged eff orts to obtain them with techniques that do not involve 
Fetal SC
In countries where abortion is allowed, fetal stem cells are obtained from aborted fetuses. This is highly controversial, concerning mainly the ethical issue of abortion, i.e the termination of a human life (Lo and Parham, 2009 ).
Adult SC
Adult stem cells can be isolated from cord blood and umbilical cord, adult blood, adult bone marrow, or other adult tissues.
Although their use does not pose the ethical issues raised by the use of human embryos, there are particular ethical issues common to all types of stem cells, especially related to the fact that after transplantation they remain in the host and may behave unpredictably in the human body (i.e. possible development of tumors). In addition, there are other relevant ethical issues such as the use of children (American Academy of Pediatrics, 2010), intellectual property and patents (Bahadur and Morrison, 2010) , economic confl icts of interest (Caulfi eld, 2010) and how the information about the basic research and clinical applications are delivered to the public through the media (Lo et al., 2008; Sugerman, 2008, Lo and Parham, 2009) . In relation to these specifi c matters, an adequate process of informed consent is a key feature. In terms of public and private cord SC banks, there is a debate over the type of information publicized in the media. Specifi cally, several private banks of umbilical stem cells can raise parents' expectations in ways not consistent with the fi ndings of the scientifi c literature (Samuel et al., 2008) . Specifi c regulations for public and private stem cell banks are needed, as well as clear information of their possible benefi ts (Smith, 2011) .
CLINICAL MEDICAL APPLICATION OF HUMAN STEM CELLS: TRANSLATIONAL MEDICINE
Embryonic Stem Cells
The regenerative capacity of ESC has been tested in preclinical studies in vitro and in animals. In Chile, treatment since 1995 has mainly involved proven ASC, especially those related to bone marrow transplantation for malignant blood diseases (Barriga F et al., 1995, Barriga et al., this issue) . They are performed primarily in academic centers and approved by Ethical Research Committees. There are some experimental studies for the treatment of Dystrophic Epidermolysis Bullosa (Conget et al., 2010) ; Osteoarticular pediatric diseases (Norambuena et al., 2012) and Amyotrophic Lateral Sclerosis with small groups of patients (Soler et al., 2011) .
Fetal Stem Cells
One phase I clinical trial is underway using neural stem cells derived from aborted fetuses for the treatment of Batten's disease (Lo and Perham, 2009 
iPS cells
In the case of iPS, it should be noted that there are complex issues to resolve, such as ensuring complete multicellular reprogramming and stability, before iPS cells can be used in regular clinical treatment. If the iPS cells and transdiff erentiated cells fi nally replace ESCs, broad ethical and scientifi c consensus could be reached among researchers with diff erent anthropological and ethical positions regarding the respect due to the human embryo. For all of those who recognize a human being in the human embryo, with the dignity and rights of a member of the human family, the iPS cells and transdiff erentiated cells is a major line of research that merits signifi cant support and work. But one should be cautious in creating too much expectation about the potential benefi ts of the use of these cells (Pietronave and Prat, 2012) .
BIOETHICAL ISSUES IN THE MEDICAL USE OF HUMAN STEM CELLS
The anthropological debate on the status of the human embryo is and has been central to the case of ESC. But there are other ethical issues common to all SC, which are related to translating biotechnological progress to clinical use. These are becoming increasingly important. (Lo et al., 2008; Lo and Parham L, 2009; Hyun, 2010a,b) . These issues, though common to all clinical research, have specifi c implications and consequences in the case of SC that require special attention. These include, among others, informed consent, (Lo et al., 2008) ; the use of children as donors (American Academy of Pediatrics Committee on Bioethics, 2010); intellectual property and the need for regulation of any patents derived from research with SC Bahadur and Morrison; , fi nancial confl icts of interest arising out of the market potential of SC, which can infl uence the direction of research, public information and equitable access to treatment (Lanoszka, 2003; Caulfi eld, 2010) . Developing countries in this regard are particularly vulnerable (Pratt and Loff , 2010) . Unlike a new drug, SC transplantation remains in the organism and its behavior is still in many respects unpredictable. In addition to these issues, there is the area of ethical and scientific implications of storing cord blood in private banks (family) and advertising and the information given to parents about their potential benefi ts (Onisto et al., 2011; cryopreservation in Chile: http://www.cryo-cell.cl/ access July, 2012; http://www. vidacel.cl/ access July, 2012). One particular bioethical issue common to the use of any SC is how to inform the public about the real contribution of SC to treat diseases, so the public may make better and more informed decisions. This poses a major responsibility for doctors and researchers to provide such information (Peddie et al., 2009 ).
Reasonable expectations of Regenerative Medicine with SC: The danger of transforming hope into hype
Regenerative Medicine based on SC therapy can dramatically change Medicine (Andersson and Lendhall, 2009 ). This hope has solid foundations in the substantial preclinical research in the laboratory and in animals with various types of SC, as well as results of some clinical ASC treatments. However, there are still serious unresolved scientifi c problems to overcome before the move to clinical use. These are mainly related to the basic safety needed for any new treatment (Hyun et al., 2008) . The problem of tumor production is one of the most relevant. The International Society for Stem Cell Research (ISSCR) (http:// www.isscr.org (access July 26, 2012) has stated that so far, the only therapy with SC incorporated as a standard medical treatment is the use of ASC for a few number of diseases with such as hematopoietic ASC transplantation for leukemia and other blood diseases, epithelial stem cells to treat burns and some problems with the cornea (Rama et al., 2010) . Bone marrow transplantation has certainly brought a qualitative improvement of great importance in medicine in recent decades (Perry and Linch, 1996) . The number of worldwide ongoing clinical trials with ASC exceeds hundreds. In the case of human ESC, only one clinical trail is currently underway (Schwartz et al., 2012) . In the case of iPS cells, there are currently more than 10 ongoing clinical trials but no treatment has been approved for regular clinical use. It is highly likely that the dynamics of research in this fi eld can reach clinically validated treatments in several other areas of medicine with diff erent types of SC.
However, public perception, the media and many patients have expectations beyond the current development of Regenerative Medicine with SC. The anguish of patients and sometimes the enthusiasm of doctors and researchers can obscure the fact that there is a long road ahead for preclinical research before safe clinical application. Scientists have noted that it is important that the great expectations raised for years with gene therapy and the very limited results may not be repeated with SC therapy (Verma, 1994; Couzin and Kaiser, 2005; Rosenecker, 2010) .
In summary, the translation from basic research to clinical practice in the case of SC raises particular ethical and scientifi c issues that currently concern both scientists and bioethicists.
Clinical trials, and innovation in Medicine
The clinical trial path. There is consensus among scientists and bioethicists that generally the safest and most responsible route for approval of new treatments is the process of approved clinical trial protocols. The experience of decades has shown the importance of this route, especially in the case of new drugs (Meadows, 2001) , which includes fi rst preclinical studies and then a sequence of clinical phases intended to test the safety and benefi ts of the new treatment known as phase I-II-III and IV. The rigorousness of this process includes scientifi c and ethical aspects The protocols must be approved by competent scientifi c and bioethical authorities. This has meant a solid advance in medicine and patient protection, becoming the paradigm of clinical research.
The path of innovation in Medicine. Beyond clinical trials. It is evident that not all medical progress has been made through the clinical trial model. This is a discussion that covers various areas of Medicine that has particular ethical dimensions (Agich, 2001) . . Progress has also been achieved by medical innovation. The classic example is Surgery. There are numerous surgical procedures that were developed outside the clinical trail scheme for reasons of their own development. Examples are laparoscopy and cardiac transplantation, among others (Cosgrove, 2008) . Something similar has happened in other areas of Medicine, especially in Pediatrics and Neonatology This route is not without risks (James and Lanman, 1976; Duc, 1995) . There are treatments that have been incorporated into regular use in the clinic, however when they have undergone clinical trials they have lost their validity, due to the contribution of evidence-based Medicine. Thus, medical doctors and patients should be aware of the uncertainties and risks involved in this course of action (Mcculloch et al., 2009 ). The issue of medical innovation out of the process of clinical research regularly, is of special interest in the case of SC and highly controversial Martell et al., 2010) .
Ethical research policy and ethics of caring for the sick.The purpose of clinical trials is to produce a general knowledge for the use of new treatments with proven eff ectiveness and safety. The good of an individual patient is not the primary objective. In the case of innovative treatments that have not been tested by clinical research protocols, the perspective is diff erent. They are covered by the fi eld of ethics of the patient care aimed at the welfare of the individual patient. The ethics of clinical research does not have the same parameters as the ethics of the individual patient care. While there is always a risk versus benefi t assessment, it requires a particular informed consent because the purpose is diff erent.
In an innovative treatment the goal is the good of the patient without knowing the outcome for certain. This requires a particular form of informed consent to guarantee the security of the patients involved to be consistent with the intended purpose. The experimental treatment plan should be reviewed by qualifi ed peers on scientifi c and ethical grounds. The results should be reported in scientifi c journals. Fulfi lling these conditions, as expressed by Lindvall and Hyun in 2009, innovative treatment outside the framework of clinical trials may be acceptable from a scientifi c and ethical perspective. These treatments should be reserved for severely ill patients who have no good treatment options. These patients are usually anxious and more interested in getting better and surviving than in expanding medical knowledge. They and their physicians should be clearly informed, given that SC will remain in the body and behave unpredictably. In order to warrant safety in innovative SC treatment more ethical considerations should be taken care of, such as clarifying the types of patients who qualify for them, maintaining adequate monitoring, taking into account the lack of evaluation of the placebo eff ect and giving consideration to the route for clinical trials if the gains are positive for a small group of patients (Cohen and Cohen, 2010b) . Although medical innovation in the treatment of patients has made signifi cant progress, major disasters have also occurred in Medicine and Surgery in the past (James and Lanman, 1976; Duc, 1995; Mello et al., 2001) . .
Stem Cell Tourism
The emergence of clinics worldwide that off er treatment with SC: The high expectations created by the potential therapeutic benefi ts of SC have had two interrelated eff ects. On the one hand, patients with severe or untreated diseases are eager to access SC treatment of diseases for which conventional treatment are ineff ective (Jawad et al., 2012) . At the same time, there is an increasing number of unregulated clinics worldwide that off er SC treatment for various diseases (Kiatpongsan and Sipp, 2009). As a result, patients suff ering from untreatable or incurable diseases are the subject to unrealistic promises, unpredictable risks, misinformation, and eventual economic exploitation (Taylor et al., 2010) . This is called "stem cell tourism" (Carrera and Bridges, 2006; Chandler, 2010; Cohen, 2010; Crozier and Thomsen, 2010; Lunt and Carrera, 2010; Murdoch and Scott, 2010; Master and Resnick, 2011; Jawad et al., 2012) . The stem cell tourism diff ers from the situation in which patients with serious illnesses, travel to qualifi ed centers in other countries to get a better treatment or more experience. We agree with Mainil et al (2012) that a better alternative terminology for this latter procedure is "'transnational health care", understood as a 'context-controlled and coordinated network of health services", which is rather diff erent from the concept of stem cell tourism.
The emergence of the stem cell tourism clinics has raised concerns among scientists and bioethicists who raise serious scientifi c and ethical issues underlying this situation about the prestige of SC research and patient safety (Nelson, 2008; Gunter et al., 2010) . In 2006 an article in Science reported there were nine research institutions around the world offering SC treatment for a range of very diff erent diseases, mainly neurological disorders (Parkinson's, Amyotrophic Lateral Sclerosis, Spinal Cord injuries, Autism, Depression), but the range included Myocardial Infarction, Diabetes, AIDS, Cancer and even infertility (Enserink, 2006) . The SC used were mainly ASC from the patient's own cord blood or from abortions (fetal). The cost of these treatments was about U.S. $20,000, excluding travel expenses and accommodations. The number of patients being treated adds up to many thousands and with results that were, in some cases, dramatic, according to the clinics involved. In 2008, Lau et al. studied 19 clinical treatment off ers, the way that the treatments are presented to the public and the clinical evidence for the treatments off ered. The results showed that treatment off erings are varied and optimistically presented. However, there was no precise information on the types of SC used, their origin and how they were administered and there was no indication if these treatments had been evaluated by experts. The information given to patients over the Internet was incomplete and could have raised public expectations without solid foundations. All clinics reported an improvement in treated patients, but without statistical support to evaluate the results. There was no clear mention of the risks. Only a few clinics mentioned problems associated with the procedure. The authors warned that the overall results do not imply the clinical assessment of each individual, because there was no access to personal information received by patients or adverse or benefi cial results.
The number of these clinics is increasing (Dolgin, 2010; Ryan et al., 2010) . They are found in Russia, Santo Domingo, Barbados, China and India, where there are fewer regulations to control such treatments (Pepper, 2010) . But there are also clinics in countries with greater safeguards, like Holland and Germany. In the mainstream print media, offers are presented optimistically, influencing the perceptions of patients (Zarzeczny et al., 2010) . China is the subject of special attention because of the high number of clinics and patients recruited. It is estimated that there are about 100 laboratories dealing with SC techniques and at least three clinics that off er treatment. By 2009, it was It was estimated that about 6500 patients would receive treatment in two of the largest clinics in China, many of them from other countries (Mcmahon and Thorsteinsdóttir, 2010a) . The lack of control over the quality of the treatments off ered led the government to implement some regulations, which have been considered inadequate and poorly enforced (Cyranoski, 2009; Nature Editorial, 2010) . Cohen and Cohen (2010a) analyzed the situation in Russia and India, where there are similar situations. The way to reach a large number of patients is primarily through the Internet. This avoids regulations in some countries that aff ect advertising media such as television and brochures. Reports of problems with unregulated SC treatment corroborate the risks of these off ers to patients and challenge the prestige of SC research and clinical use. For example, there is a report of a child in Moscow, Russia, with a brain tumor after being injected with fetal neural stem cells in the cerebrospinal fl uid (Amariglio, 2009; Macready, 2009 ). In Thailand a child developed a special form of tumor after a clinic injected autologous ASC to the kidney (Thirabanjasak et al., 2010; Cyranoski, 2010a) . In Korea, two patients died after SC treatment (Cyranoski, 2010b ) and in Germany a child with Cerebral Palsy died after SC was injected in the brain (Tuff s, 2010) .
The urgency to establish regulations
The situation described above has prompted the scientifi c community and bioethicists to seek regulatory criteria and requirements for information to protect patients and their relatives (Cohen and Cohen, 2010b) . For this to be eff ective in an increasingly globalized and interconnected world, it is necessary that there be international agreements among nations Manzotti, 2010, Schalev, 2010) . (2008) , commenting on these guidelines, state that SC clinical research involves specific aspects that need to be treated carefully. In agreement with other researchers (Lo and Parham, 2009; Lo et al., 2008) , they emphasize the following: the review of treatment protocols by SC experts; the need to clearly defi ne the origin, quality and handling of the SC used; the informed consent process requires additional aspects compared to the one generally used in scientifi c research, such as information regarding scientifi c and ethical aspects of particular relevance, especially when they involved the destruction of embryos, the risks involved with different types of SC and the possibility of adverse eff ects, and the lack of knowledge about long-term effects, etc., regular monitoring of the participants in research to ensure their welfare,transparency in communicating the positive and negative outcomes, and adverse eff ects and social justice in access to treatment.
Recommendations for treatments of medical innovation beyond clinical trials:
The ISSCR guidelines assume that if certain requirements are met treatments beyond clinical trials can be ethically and scientifi cally valid for application to a small group of patients with severe and intractable diseases http://www.isscr.org/GuidelinesforClinicalTranslation/2480. htm (access July 26, 2012) . Given the novelty of the SC, they can have unpredictable behavior that must be considered by doctors and informed patients. The summary of these requirements is: There must be a written protocol of the procedure (including scientific consistency for use with a particular patient or small group; justify its use as opposed to other possible treatments, characterization of the SCs to be used: origin, type, in vitro manipulation, specify method of administration; follow-up plan and monitoring to assess eff ects and eff ectiveness); written approval by competent reviewers not involved in the investigation; medical institution and the doctor performing the treatment should take responsibility for this; the institution must have competent personnel and adequate facilities; informed consent must be complete and transparent (It should be determined if the patient has understood that it is an unproven intervention and the possible risks and benefi ts); regular medical checkups and plan for possible adverse eff ects; the purpose of the research in contributing to SC research and the generalization of the results should be made explicit by those responsible for the research (this includes: systematic evaluation of the result, communication of results, plan to move to clinical trials in adequate time).
Increased offers of SC treatments in clinics in several countries around the world moved the ISSCR in 2010 to publish the Patient Handbook on Stem Cell Therapies, which is available in several languages /http://www.isscr.org/The_ Patient_Handbook.htm; access July 26, 2012).
The debate about regulation and patients' autonomy:
This issue is still debated. The International Cellular Medicine Society (ICMS) is an organization formed by scientists, doctors and patient, with the aim of cooperating in informing and educating physicians and patients about the use of and advancement in SCs. The ICMS has a record of the clinics that off er treatment and also provides guidance on quality and safety (http://www.cellmedicinesociety.org/ access July 26, 2012). According to the ICMS, the ISSCR guidelines are more oriented to research and interfere with the autonomy of patients and physicians to use well-regulated SC beyond clinical trials. The debate continues through open letters on the position by both institutions (Audley, 2011; Sipp, 2011) .
Finally, we must consider the issue of doctors who use drugs that are experimental or that are used for treatments which they have not been approved for (Okie, 2006; Radley et al., 2006; Lat et al., 2011) . This is a relatively common practice. However, it is essential to consider diff erences between SC and drugs. SC will live for a long time and can aff ect the patient with unexpected responses and changes depending on environmental signals and intrinsic properties (Ginis and Rao, 2003) . The use of SC by some clinics has provoked the intervention of the Federal Drug Administration (FDA) (Cyranoski, 2010) . These clinics have defended their position and claim to follow the ISCM guidelines. An article in Nature in 2010 mentioned the lawsuit fi led by the FDA against a clinic that was using SC for the orthopedic regeneration. Its medical director C. Centeno defended his position and reported his results in scientifi c journals (Centeno et al., 2010) . Some policies have been established concerning the information provided by SC clinics. According to these policies, there is arguably an ethical duty to provide potential clients of the clinics with the best available information about the risks and benefi ts of what is essentially an experimental treatment.
Patients affected by untreatable diseases often turn to alternative or natural Medicine, which in many cases does not have a scientifi c basis. Nobody considers that they do not have the right to do this. But, is this comparable to the case of SC tourism?. We think not. Stem cells remain in the patient's body and can have unexpected harmful eff ects as in the cases cited above.
CONCLUSIONS
The ethical aspects of research and clinical application of SC are very important. Initially the main ethical debate related to the moral status of the human embryo. While this remains an important issue, new scientifi c developments, and especially the transfer to clinical application of SC, have raised additional ethical challenges.
The hope of curing various diseases has produced disproportionate excitement in the public that does not correlate with the current status of the clinical use of SC. The existence of unregulated clinics that off er SC treatment, in most cases with serious scientifi c and ethical shortcomings, has led to hundreds of anxious patients going to these clinics with great expectations and at great cost. Moreover, this jeopardizes the prestige of research in this fi eld.
The scientifi c community and bioethicists have responded to this situation by providing guidelines for the licit translation from the pre-clinical research to the clinic and providing patients with information on clinics off ering SC treatments and how to evaluate the decision to go to them.
We also addressed the issue of innovation and medical progress beyond clinical trials and the scientifi c and ethical requirements for these exceptional cases. It is not easy to make a clear separation between what is medical tourism and accepted clinical innovation according to precise parameters.
In the future it will be necessary to establish global guidelines and regulations implying an agreement among countries to eff ectively protect patients and ensure the proper use of the amazing advances expected with SC treatment and research for the sake of science and of all patients considering the requirements of social justice worldwide. 
